Showing results (51-60 of 161) with videos related to
Sort By:
Pageof 17
Inflammatory Bowel Diseases|December 3, 2014
Role of G protein-coupled orphan receptors in intestinal inflammation: novel targets in inflammatory bowel diseasesAndrzej Wasilewski, Martin Storr, Marta Zielińska, et al.Journal of Neurogastroenterology and Motility|September 10, 2015
Probiotic Therapy of the Irritable Bowel Syndrome: Why Is the Evidence Still Poor and What Can Be Done About It?Nazar Mazurak, Ellen Broelz, Martin Storr, et al.Journal of Neurogastroenterology and Motility|February 28, 2017
Future Treatment of Constipation-associated Disorders: Role of Relamorelin and Other Ghrelin Receptor AgonistsPaula Mosińska, Hubert Zatorski, Martin Storr, et al.Zeitschrift Fur Gastroenterologie|February 8, 2021
[Treatment of IBS with Lactobacillus plantarum 299v: Therapeutic success increases with length of treatment - real-life data of a non-interventional study in Germany]Heiner Krammer, Martin Storr, Ahmed Madisch, et al.Current Drug Targets|June 19, 2013
Nociceptin / orphanin FQ (NOP) receptors as novel potential target in the treatment of gastrointestinal diseasesMarta Sobczak, Maciej Sałaga, Martin Storr, et al.Current Drug Targets|December 30, 2017
Efficacy and Safety of Serotonin Receptor Ligands in the Treatment of Irritable Bowel Syndrome: A ReviewAgata Binienda, Martin Storr, Jakub Fichna, et al.Neurogastroenterology and Motility|December 15, 2018
Enkephalinase inhibitors, potential therapeutics for the future treatment of diarrhea predominant functional gastrointestinal disordersAgata Szymaszkiewicz, Martin Storr, Jakub Fichna, et al.Inflammatory Bowel Diseases|March 31, 2015
Beneficial Effects of Probiotics, Prebiotics, Synbiotics, and Psychobiotics in Inflammatory Bowel DiseaseAndrzej Wasilewski, Marta Zielińska, Martin Storr, et al.Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology|January 29, 2016
RGS proteins as targets in the treatment of intestinal inflammation and visceral pain: New insights and future perspectivesMaciej Salaga, Martin Storr, Kirill A Martemyanov, et al.Therapeutics and Clinical Risk Management|June 4, 2016
Clinical potential of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndromeAleksandra Sobolewska-Włodarczyk, Marcin Włodarczyk, Martin Storr, et al.Pageof 17